IRF2 and central nervous system cancer: Overall survival curves indicated that glioma patients with lower IRF1 (p = 4.42E-33), IRF2 (p = 2.22E-16), IRF3 (p = 1.43E-15), IRF4 (p = 0.004), IRF5 p = 5.84E-12), IRF7 (p = 6.85E-28), IRF8 (p = 0.001), and IRF9 (p = 0.000) transcript levels had significantly longer overall survival times (Figure 4).